JP2023537980A5 - - Google Patents
Info
- Publication number
- JP2023537980A5 JP2023537980A5 JP2023509770A JP2023509770A JP2023537980A5 JP 2023537980 A5 JP2023537980 A5 JP 2023537980A5 JP 2023509770 A JP2023509770 A JP 2023509770A JP 2023509770 A JP2023509770 A JP 2023509770A JP 2023537980 A5 JP2023537980 A5 JP 2023537980A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide sequence
- seq
- identity
- nucleic acid
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063064431P | 2020-08-12 | 2020-08-12 | |
| US63/064,431 | 2020-08-12 | ||
| PCT/EP2021/072365 WO2022034130A1 (en) | 2020-08-12 | 2021-08-11 | Gene therapy using nucleic acid constructs comprising methyl cpg binding protein 2 (mecp2) promoter sequences |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023537980A JP2023537980A (ja) | 2023-09-06 |
| JP2023537980A5 true JP2023537980A5 (https=) | 2024-07-25 |
Family
ID=77655525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023509770A Pending JP2023537980A (ja) | 2020-08-12 | 2021-08-11 | メチルｃｐｇ結合タンパク質２（ｍｅｃｐ２）プロモータ配列を含む核酸構築体を用いた遺伝子治療 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20230295657A1 (https=) |
| EP (1) | EP4196171A1 (https=) |
| JP (1) | JP2023537980A (https=) |
| KR (1) | KR20230044506A (https=) |
| CN (1) | CN116113441A (https=) |
| AR (1) | AR123206A1 (https=) |
| AU (1) | AU2021325717A1 (https=) |
| BR (1) | BR112023002374A2 (https=) |
| CA (1) | CA3188748A1 (https=) |
| CL (1) | CL2023000419A1 (https=) |
| CO (1) | CO2023000444A2 (https=) |
| EC (1) | ECSP23016688A (https=) |
| IL (1) | IL300294A (https=) |
| MX (1) | MX2023001701A (https=) |
| PE (1) | PE20230914A1 (https=) |
| PH (1) | PH12023550145A1 (https=) |
| TW (1) | TWI902867B (https=) |
| WO (1) | WO2022034130A1 (https=) |
| ZA (1) | ZA202300378B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240033332A1 (en) * | 2020-12-17 | 2024-02-01 | Kyoto University | Agent for activating a neuron |
| GB202216168D0 (en) | 2022-10-31 | 2022-12-14 | UCB Biopharma SRL | Route of administration |
| WO2024163823A1 (en) * | 2023-02-02 | 2024-08-08 | Shape Therapeutics Inc. | Tissue-specific enhancers for regulating transcription |
| JP2026509301A (ja) * | 2023-03-14 | 2026-03-17 | ユーシービー バイオファルマ エスアールエル | 遺伝子治療 |
| CN121335978A (zh) * | 2023-06-16 | 2026-01-13 | 舒泰神（北京）生物制药股份有限公司 | 一种人源MeCp2启动子及其用途 |
| WO2025213097A1 (en) * | 2024-04-05 | 2025-10-09 | The Children's Hospital Of Philadelphia | Novel gene therapy constructs for stxbp1 haploinsufficiency |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3075858T3 (pl) * | 2007-12-21 | 2020-07-13 | Novartis Ag | Ssaczy wektor ekspresyjny |
| EA201492116A1 (ru) * | 2012-05-16 | 2015-05-29 | Рана Терапьютикс, Инк. | Композиции и способы для модулирования экспрессии mecp2 |
| GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| WO2016077687A1 (en) * | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| EP4344741A3 (en) * | 2014-11-21 | 2024-08-28 | The University of North Carolina at Chapel Hill | Aav vectors targeted to the central nervous system |
| WO2016100575A1 (en) * | 2014-12-16 | 2016-06-23 | Board Of Regents Of The University Of Nebraska | Gene therapy for juvenile batten disease |
| US20190328906A1 (en) * | 2016-03-02 | 2019-10-31 | The Children's Hospital Of Philadelphia | Therapy for frontotemporal dementia |
| TWI601821B (zh) * | 2016-04-15 | 2017-10-11 | 中央研究院 | 治療神經發展性疾病 |
| CN113166781A (zh) * | 2018-10-15 | 2021-07-23 | 沃雅戈治疗公司 | 在杆状病毒/Sf9系统中大规模生产rAAV的表达载体 |
-
2021
- 2021-08-11 BR BR112023002374A patent/BR112023002374A2/pt unknown
- 2021-08-11 PH PH1/2023/550145A patent/PH12023550145A1/en unknown
- 2021-08-11 MX MX2023001701A patent/MX2023001701A/es unknown
- 2021-08-11 AU AU2021325717A patent/AU2021325717A1/en active Pending
- 2021-08-11 IL IL300294A patent/IL300294A/en unknown
- 2021-08-11 KR KR1020237007287A patent/KR20230044506A/ko active Pending
- 2021-08-11 CN CN202180056525.5A patent/CN116113441A/zh active Pending
- 2021-08-11 PE PE2023000142A patent/PE20230914A1/es unknown
- 2021-08-11 US US18/021,005 patent/US20230295657A1/en active Pending
- 2021-08-11 WO PCT/EP2021/072365 patent/WO2022034130A1/en not_active Ceased
- 2021-08-11 AR ARP210102238A patent/AR123206A1/es unknown
- 2021-08-11 CA CA3188748A patent/CA3188748A1/en active Pending
- 2021-08-11 TW TW110129603A patent/TWI902867B/zh active
- 2021-08-11 EP EP21766127.1A patent/EP4196171A1/en active Pending
- 2021-08-11 JP JP2023509770A patent/JP2023537980A/ja active Pending
-
2023
- 2023-01-09 ZA ZA2023/00378A patent/ZA202300378B/en unknown
- 2023-01-16 CO CONC2023/0000444A patent/CO2023000444A2/es unknown
- 2023-02-10 CL CL2023000419A patent/CL2023000419A1/es unknown
- 2023-03-08 EC ECSENADI202316688A patent/ECSP23016688A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023537980A5 (https=) | ||
| JP2022060228A5 (https=) | ||
| IL278213B1 (en) | A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd) | |
| IL300294A (en) | Gene therapy using nucleic acid constructs containing methyl CPG-binding protein 2 (MECP2) promoter sequences | |
| JP2022535749A5 (https=) | ||
| JP7853952B2 (ja) | Ｇｌｕｔ１発現のためのアデノ随伴ウイルスベクターおよびその使用 | |
| JP7616995B2 (ja) | 神経変性疾患のための遺伝子治療 | |
| JP2017513861A (ja) | 末梢性ニューロパチー及び運動ニューロン疾患の治療方法 | |
| JP2023537625A5 (https=) | ||
| JP2022531809A5 (https=) | ||
| JP2022541070A5 (https=) | ||
| US20240318199A1 (en) | Adeno-associated virus (aav) systems for treatment of progranulin associated neurodegenerative diseases or disorders | |
| RU2018145010A (ru) | Оптимизированные гены и экспрессионные кассеты cln1, и их применение | |
| JP2022511453A5 (https=) | ||
| JP2020054367A (ja) | 改変ｇ６ｐｃをコードするアデノ随伴ウイルスベクターおよびその使用 | |
| IL262852B1 (en) | Treatment of complement-mediated disorders | |
| JP2020519629A5 (https=) | ||
| JP2017529395A5 (https=) | ||
| FI3373980T3 (fi) | Menetelmiä lihasdystrofian hoitamiseksi | |
| JP2020509786A5 (https=) | ||
| JP2023500793A5 (https=) | ||
| JP2021520811A5 (https=) | ||
| CN114144518A (zh) | 用于基因疗法的双亮氨酸拉链激酶抑制剂 | |
| CA3122319A1 (en) | Expression cassettes for gene therapy vectors | |
| JP2021534766A5 (https=) |